keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal Serogroup B Vaccine

keyword
https://www.readbyqxmd.com/read/29410413/crystal-structure-reveals-vaccine-elicited-bactericidal-human-antibody-targeting-a-conserved-epitope-on-meningococcal-fhbp
#1
Jacinto López-Sagaseta, Peter T Beernink, Federica Bianchi, Laura Santini, Elisabetta Frigimelica, Alexander H Lucas, Mariagrazia Pizza, Matthew J Bottomley
Data obtained recently in the United Kingdom following a nationwide infant immunization program against serogroup B Neisseria meningitidis (MenB) reported >80% 4CMenB vaccine-mediated protection. Factor H-binding protein (fHbp) is a meningococcal virulence factor and a component of two new MenB vaccines. Here, we investigated the structural bases underlying the fHbp-dependent protective antibody response in humans, which might inform future antigen design efforts. We present the co-crystal structure of a human antibody Fab targeting fHbp...
February 6, 2018: Nature Communications
https://www.readbyqxmd.com/read/29406154/meningococcal-disease-and-control-in-china-findings-and-updates-from-the-global-meningococcal-initiative-gmi
#2
REVIEW
Junhong Li, Zhujun Shao, Gang Liu, Xilian Bai, Ray Borrow, Min Chen, Qinglan Guo, Yue Han, Yixing Li, Muhamed-Kheir Taha, Xihai Xu, Xin Xu, Huizhen Zheng
The Global Meningococcal Initiative (GMI) is a global expert group, including scientists, clinicians and public health officials from a wide range of specialities. The goal of the GMI is to prevent meningococcal disease worldwide through education, research, and co-operation. The Chinese GMI roundtable meeting was held in June 2017. The GMI met with local experts to gain insight into the meningococcal disease burden in China and current prevention and vaccination strategies in place. China experienced five epidemics of serogroup A meningococcal disease (MenA) between 1938 and 1977, with peak incidence of 403/100,000 recorded in 1967...
January 31, 2018: Journal of Infection
https://www.readbyqxmd.com/read/29393713/modeling-excess-zeroes-in-an-integrated-analysis-of-vaccine-safety
#3
Roger Maansson, David Radley, Qin Jiang, Johannes Beeslaar, Scott Patterson, Judith Absalon, John Perez
In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA)...
February 2, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29380290/menb-fhbp-meningococcal-group%C3%A2-b-vaccine-trumenba%C3%A2-a-review-in-active-immunization-in-individuals-aged%C3%A2-%C3%A2-%C3%A2-10%C3%A2-years
#4
Matt Shirley, Muhamed-Kheir Taha
MenB-FHbp (bivalent rLP2086; Trumenba®) is a recombinant protein-based vaccine targeting Neisseria meningitidis serogroup B (MenB), which has recently been licensed in the EU for active immunization to prevent invasive disease caused by MenB in individuals ≥ 10 years of age. The vaccine, which contains a variant from each of the two identified subfamilies of the meningococcal surface protein factor H-binding protein (fHBP), has been licensed in the USA for active immunization in individuals 10-25 years of age since 2014...
January 29, 2018: Drugs
https://www.readbyqxmd.com/read/29374982/protecting-uk-adolescents-and-adults-against-meningococcal-serogroup-b-disease
#5
Andrew Vyse, Gillian Ellsbury, Harish Madhava
Meningococcal serogroup B disease (MenB) is endemic in the UK and continues to cause the majority of invasive meningococcal disease. Two broadly protective protein based MenB vaccines are now licensed and available, both with wide age indications. Whilst the UK recently became the first country to routinely vaccinate infants against MenB, a recommendation has not yet been extended to older age groups who can also now benefit from these vaccines. Areas covered: This review summarizes the evidence supporting the rationale for adolescents and adults in the UK to consider MenB vaccination...
January 29, 2018: Expert Review of Vaccines
https://www.readbyqxmd.com/read/29371070/immunogenicity-and-safety-of-the-multicomponent-meningococcal-b-vaccine-4cmenb-in-children-and-adolescents-a-systematic-review-and-meta-analysis
#6
Maria Elena Flacco, Lamberto Manzoli, Annalisa Rosso, Carolina Marzuillo, Mario Bergamini, Armando Stefanati, Rosario Cultrera, Paolo Villari, Walter Ricciardi, John P A Ioannidis, Despina G Contopoulos-Ioannidis
BACKGROUND: The multicomponent meningococcal serogroup B vaccine (4CMenB) has been licensed in more than 35 countries. However, uncertainties remain about the lowest number of doses required to induce satisfactory, persistent immune responses. We did a systematic review and meta-analysis to provide quantitative estimates for the immunogenicity, persistence of immunogenicity, and safety of 4CMenB vaccine in children and adolescents. METHODS: For this systematic review and meta-analyses (proportion, head to head, and network), we searched MEDLINE, Scopus, Embase, and ClinicalTrials...
January 19, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29337653/safety-and-immunogenicity-of-a-meningococcal-b-recombinant-vaccine-when-administered-with-routine-vaccines-to-healthy-infants-in-taiwan-a-phase-3-open-label-randomized-study
#7
Nan-Chang Chiu, Li-Min Huang, Arnold Willemsen, Chiranjiwi Bhusal, Ashwani Kumar Arora, Zenaida Reynoso Mojares, Daniela Toneatto
Neisseria meningitidis is associated with high mortality and morbidity in infants and children worldwide. This phase 3 study (NCT02173704) evaluated safety and immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine (4CMenB) co-administered with routine vaccines in Taiwanese infants. In total, 225 healthy infants were randomized (2:1) to receive 4CMenB and routine vaccines (4CMenB+Routine) or routine vaccines only (Routine group) at 2, 4, 6 and 12 months of age. Routine vaccines were diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b, 13-valent pneumococcal, hepatitis B, measles-mumps-rubella and varicella vaccines...
January 16, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29329168/immune-responses-to-booster-vaccination-with-meningococcal-abcwy-vaccine-following-primary-vaccination-with-either-investigational-or-licensed-vaccines-a-phase-2-randomized-study
#8
Leszek Szenborn, Stan L Block, Teresa Jackowska, Ryszard Konior, Diego DʼAgostino, Igor Smolenov, Daniela Toneatto, Jo Anne Welsch
BACKGROUND: Current meningococcal prime-boost vaccination schedules include separate vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis serogroups. METHODS: In this phase 2, randomized, observer-blind, extension study (NCT01272180), participants aged 10-25 years received 1 booster dose of MenABCWY vaccine at 24 months (M) post-primary series of either MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose)...
January 11, 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29301718/-immunisation-schedule-of-the-spanish-association-of-paediatrics-2018-recommendations
#9
David Moreno-Pérez, Francisco José Álvarez García, Javier Álvarez Aldeán, María José Cilleruelo Ortega, María Garcés Sánchez, Nuria García Sánchez, Ángel Hernández Merino, María Méndez Hernández, Manuel Merino Moína, Abián Montesdeoca Melián, Jesús Ruiz-Contreras
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics annually publishes the immunisation schedule considered optimal for children resident in Spain, according to available evidence on current vaccines. Regarding funded immunisations, 2+1 strategy (2, 4, 11-12 months) with hexavalent (DTPa-IPV-Hib-HB) and 13-valent pneumococcal vaccines are recommended. Administration of the 6-year booster dose with DTPa is recommended, and a poliomyelitis dose for children who had received the 2+1 scheme, as well as Tdap vaccine for adolescents and pregnant women in every pregnancy between 27 and 32 weeks' gestation...
January 2018: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/29287682/development-of-an-fhbp-ctb-holotoxin-like-chimera-and-the-elicitation-of-bactericidal-antibodies-against-serogroup-b-neisseria-meningitidis
#10
Gregory A Price, Margaret C Bash
The Neisseria meningitidis factor H binding protein (FHbp) is an important virulence factor and vaccine antigen contained in both USA licensed serogroup B meningococcal vaccines. Recent studies in human factor H (hFH) transgenic mice suggest that hFH-FHbp interactions lower FHbp-elicited immunogenicity. To provide tools with which to characterize and potentially improve FHbp immunogenicity, we developed an FHbp-cholera holotoxin-like chimera vaccine expression system in Escherichia coli that utilizes cholera toxin B (CTB) as both a scaffold and adjuvant for FHbp...
December 26, 2017: Vaccine
https://www.readbyqxmd.com/read/29203096/meningococcal-disease-a-clinical-and-epidemiological-review
#11
REVIEW
Rodrigo Siqueira Batista, Andréia Patrícia Gomes, Jorge Luiz Dutra Gazineo, Paulo Sérgio Balbino Miguel, Luiz Alberto Santana, Lisa Oliveira, Mauro Geller
Meningococcal disease is the acute infection caused by Neisseria meningitidis, which has humans as the only natural host. The disease is widespread around the globe and is known for its epidemical potential and high rates of lethality and morbidity. The highest number of cases of the disease is registered in the semi-arid regions of sub-Saharan Africa. In Brazil, it is endemic with occasional outbreaks, epidemics and sporadic cases occurring throughout the year, especially in the winter. The major epidemics of the disease occurred in Brazil in the 70's caused by serogroups A and C...
November 2017: Asian Pacific Journal of Tropical Medicine
https://www.readbyqxmd.com/read/29183735/meningococcal-carriage-among-a-university-student-population-united-states-2015
#12
Lucy Breakwell, Melissa Whaley, Unab I Khan, Utpala Bandy, Nicole Alexander-Scott, Lynn Dupont, Cindy Vanner, How-Yi Chang, Jeni T Vuong, Stacey Martin, Jessica R MacNeil, Xin Wang, Sarah A Meyer
OBJECTIVES: Several outbreaks of serogroup B meningococcal disease have occurred among university students in recent years. In the setting of high coverage of the quadrivalent meningococcal conjugate vaccine and prior to widespread use of serogroup B meningococcal vaccines among adolescents, we conducted surveys to characterize the prevalence and molecular characteristics of meningococcal carriage among university students. METHODS: Two cross-sectional oropharyngeal carriage surveys were conducted among undergraduates at a Rhode Island university...
November 25, 2017: Vaccine
https://www.readbyqxmd.com/read/29176349/epidemiology-of-community-acquired-bacterial-meningitis
#13
Matthijs C Brouwer, Diederik van de Beek
PURPOSE OF REVIEW: The epidemiology of bacterial meningitis has been dynamic in the past 30 years following introduction of conjugated vaccines against Haemophilus influenzae type B, Streptococcus pneumoniae and Neisseria meningitidis. The purpose of this review is to describe recent developments in bacterial meningitis epidemiology. RECENT FINDINGS: The incidence of bacterial meningitis in Western countries (Finland, Netherlands, and the United States) gradually declined by 3-4% per year to 0...
February 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29170349/52%C3%A2-loop-mediated-isothermal-amplification-pcr-lamp-for-the-rapid-identification-of-invasive-meningococcal-disease-in-the-emergency-department
#14
Thomas Waterfield, Bethany Patenall, James McKenna, Derek Fairley
BACKGROUND: Despite successful vaccination programmes meningococcal disease (MD) remains the leading infectious cause of septicaemia and death in children in the UK and Ireland.1,2 The early diagnosis of MD significantly improves outcomes with reduced morbidity and mortality.1,2 The early stages of MD are often indistinguishable from a simple viral illness making an early positive diagnosis of MD difficult.1 Hibergene have developed a commercially available bedside Loop-mediated isothermal AMPlification PCR (LAMP-MD) test that is a highly sensitive 0...
December 2017: Emergency Medicine Journal: EMJ
https://www.readbyqxmd.com/read/29164681/urticarial-vasculitis-after-meningococcal-serogroup-b-vaccine-in-a-6-year-old-girl
#15
Virginia Velasco-Tamariz, Marta Prieto-Barrios, Fátima Tous-Romero, Sara Isabel Palencia-Pérez, Concepción Postigo-Llorente
The first vaccine that shows significant potential in providing broad coverage against serogroup B meningococcal disease has recently been approved. Because of its newness, potential adverse events need to be reported. Here we report a case of urticarial vasculitis, a rare disease in children, in probable relationship with the novel vaccine.
November 21, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/29152576/meningococcal-antigen-typing-system-mats-based-neisseria-meningitidis-serogroup-b-coverage-prediction-for-the-menb-4c-vaccine-in-the-united-states
#16
Gowrisankar Rajam, Maria Stella, Ellie Kim, Simon Paulos, Giuseppe Boccadifuoco, Laura Serino, George Carlone, Duccio Medini
Neisseria meningitidis is the most common cause of bacterial meningitis in children and young adults worldwide. A 4-component vaccine against N. meningitidis serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H binding protein (fHBP), neisserial heparin binding protein (NHBA), neisserial adhesin A (NadA), and PorA-containing outer membrane vesicles was recently approved for use in the United States and other countries worldwide. Because the public health impact of MenB-4C in the United States is unclear, we used the meningococcal antigen typing system (MATS) to assess the strain coverage in a panel of strains representative of serogroup B (NmB) disease in the United States...
November 2017: MSphere
https://www.readbyqxmd.com/read/29136861/quality-by-design-approach-in-the-development-of-an-ultra-high-performance-liquid-chromatography-method-for-bexsero-meningococcal-group-b-vaccine
#17
Luca Nompari, Serena Orlandini, Benedetta Pasquini, Cristiana Campa, Michele Rovini, Massimo Del Bubba, Sandra Furlanetto
Bexsero is the first approved vaccine for active immunization of individuals from 2 months of age and older to prevent invasive disease caused by Neisseria meningitidis serogroup B. The active components of the vaccine are Neisseria Heparin Binding Antigen, factor H binding protein, Neisseria adhesin A, produced in Escherichia coli cells by recombinant DNA technology, and Outer Membrane Vesicles (expressing Porin A and Porin B), produced by fermentation of Neisseria meningitidis strain NZ98/254. All the Bexsero active components are adsorbed on aluminum hydroxide and the unadsorbed antigens content is a product critical quality attribute...
February 1, 2018: Talanta
https://www.readbyqxmd.com/read/29126310/current-epidemiology-and-trends-in-meningococcal-disease-united-states-1996-2015
#18
Jessica R MacNeil, Amy E Blain, Xin Wang, Amanda C Cohn
Background: In 2005, meningococcal conjugate vaccine (MenACWY) was recommended for routine use among adolescents aged 11-18 years. This report describes the epidemiologic features of meningococcal disease and trends in meningococcal disease incidence following MenACWY introduction in the United States. Methods: Incidence rates and case-fatality ratios by age group and serogroup during 2006-2015 were calculated using data from the National Notifiable Diseases Surveillance System (NNDSS); changes in incidence during this time were evaluated...
November 8, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29092704/epidemiology-of-invasive-meningococcal-b-disease-in-australia-1999-2015-priority-populations-for-vaccination
#19
Brett N Archer, Clayton K Chiu, Sanjay H Jayasinghe, Peter C Richmond, Jodie McVernon, Monica M Lahra, Ross M Andrews, Peter B McIntyre
OBJECTIVES: To describe trends in the age-specific incidence of serogroup B invasive meningococcal disease (IMD) in Australia, 1999-2015. DESIGN, SETTING, PARTICIPANTS: Analysis in February 2017 of de-identified notification data from the Australian National Notifiable Diseases Surveillance System of all notifications of IMD in Australia with a recorded diagnosis date during 1999-2015.Major outcomes: IMD notification rates in Australia, 1999-2015, by age, serogroup, Indigenous status, and region...
November 6, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/29065137/differences-in-the-population-structure-of-neisseria-meningitidis-in-two-australian-states-victoria-and-western-australia
#20
Shakeel Mowlaboccus, Christopher A Mullally, Peter C Richmond, Benjamin P Howden, Kerrie Stevens, David J Speers, Anthony D Keil, Ottar N Bjørnstad, Timothy T Perkins, Charlene M Kahler
Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD). A recombinant vaccine called Bexsero® incorporates four subcapsular antigens (fHbp, NHBA, NadA and PorA) which are used to assign a Bexsero® antigen sequence type (BAST) to each meningococcal strain. The vaccine elicits an immune response against combinations of variants of these antigens which have been grouped into specific BAST profiles that have been shown to have different distributions within geographical locations thus potentially affecting the efficacy of the vaccine...
2017: PloS One
keyword
keyword
49014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"